ErascaERAS
Recorded

Erasca 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration23 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul JengAnalyst

We'll get started. Welcome to this next session. Our next presenting company is Erasca. My name is Paul Jeng. I am one of the biotech analysts with Guggenheim, and I am very pleased to be joined today by Jonathan Lim, Chairman and CEO, and David Chacko, CFO and CBO from Erasca. Thanks for joining, guys. Thanks, Paul.

Paul JengAnalyst

Great to be here. Maybe a good place to start is just to provide a quick intro to the company and your pipeline for those who might be newer to the story.

Jonathan LimChairman and CEO

Yeah. Erasca was formed in 2018 around the premise of erasing cancer and eradicating RAS-driven cancer. In fact, that mission is in our name, and we since then have built a pipeline. We have gone after the MAP kinase pathway broadly, but we have really settled on focusing entirely on RAS with a pipeline that we are very excited about. We have ERAS-0015, a pan-RAS molecular glue that is focused on really targeting RAS broadly in terms of all the key mutations, including also RAS wild type in terms of K, H, and N. Then we also have ERAS-4001, which is a pan-KRAS small molecule inhibitor. It is a switch II pocket binder that spares H and N-RAS, but hits K-RAS really hard. We are also excited about the prospect of putting those two molecules together, which I know we will talk about later.

Paul JengAnalyst

Okay, great. ERAS-0015, your pan-RAS inhibitor, had a couple updates this year, April and July, which were really interesting. I was hoping you could first start by perhaps recapping the data that you showed, efficacy and safety profile. Then looking forward, you will have some updates for the program at the upcoming Triple Meeting in November, so maybe set some expectations with that in the context of what you already shown.

Jonathan LimChairman and CEO

Yeah. We're really excited about ERAS-0015 pan-RAS program. Basically, what we've shown in April and July corporate disclosures is very compelling single-agent activity in both pancreatic cancer as well as non-small cell lung cancer, as well as safety and tolerability. As we look towards the Triple Meeting, we have an oral plenary presentation, and this is really geared towards the more the scientific audience. For most clinicians, they're aware of our data, but I think there's some clinicians where, when we've given corporate updates, those data may not be as visible as they would be in a scientific conference. So this is really a coming out, so to speak, for the scientific data.

Jonathan LimChairman and CEO

Now, what we've shown in the April and July disclosures is in pancreatic cancer, monotherapy activity that's somewhere in the 40%-57% response rate, and that really depends on line of treatment, as well as dose. So what we're hoping with the upcoming data disclosure is, first of all, more patients enrolled, especially at what we call RDE, which are the recommended doses for expansion at 24 and 32 milligrams. So I think that's something to pay attention to, because in that July dataset, we did see a pretty striking dose response. So we had higher response rates at the highest response rates were at 32 milligrams, and the lowest response rates were at 16, and then 24 was somewhere in between.

Jonathan LimChairman and CEO

So I think we're going to want to pay attention to sort of the 32 milligram dose especially, and then also 24 milligram, and then just see whether that response rate lands within that 40%-57% range. I think we're going to want to see the line of treatment. We're also going to want to see the mutation breakout. I think there's an opportunity, especially for G12D, to show an opportunity for improvement over what's been reported for the comparator, where in FDA documents, it looked like the response rate was 24% against G12D. So I think in the July dataset, when you look at sort of what's been publicly disclosed, I think people have come to the conclusion that G12D along a dose range was somewhere in the 50% zip code.

Jonathan LimChairman and CEO

As we show more data at the 24 and 32 milligram doses, are we sort of landing in that 50+% range? Then in an all-comers, if we're able to land somewhere in the, call it, mid-40s or so, that still would be about 10 to 20 points differentiated versus what's been reported in the past with response rates in the 25%-32% range. I think that's how we look at pancreatic is, it's really exciting what's been achieved by daraxonrasib in the second-line setting, but I think there's an opportunity for better efficacy, as well as when you look at the safety and tolerability side of the equation, I think interruptions and dose reductions have reported in the New England Journal paper have been quite high in that 36%-56% range.

Jonathan LimChairman and CEO

I think ultimately, we hope to be able to show improvements in the frequency and severity of rash, GI, and stomatitis, but ultimately, how do those translate into maintaining dose for patients to deliver the optimal dose to patients in a really aggressive tumor type like pancreatic. If we're able to show meaningfully lower dose interruptions and reductions, we think that's the other side of the equation that's really important. Then finally, for lung cancer, what we've reported previously was response rates in the 60+% range. If you look at the best targeted therapies in KRAS G12X, divarasib is sort of an example of a very potent G12C molecule that has achieved response rates in the 56%-59% range.

Jonathan LimChairman and CEO

I think if we hold at or above that threshold in a non-G12C space, which actually is less sensitive to target inhibition than G12C tumors, which tend to be a little more sensitive to targeted therapy, then we'll be feeling very good going into the pivotal trials next year in second line plus, as well as first line, that we have a very promising lung cancer drug. I think the totality of efficacy and safety in terms of what we've reported, we hope to have longer follow-up for these patients, hopefully more confirmed response rates than unconfirmed. Then I think if we sort of hold within those target ranges, then we'll really have a differentiated drug.

Paul JengAnalyst

Okay. Yeah, super helpful. Any sense of, I guess, the scope of the data in terms of patient numbers we should expect?

Jonathan LimChairman and CEO

Yeah, I think meaningfully higher. I think especially because we've been putting our thumb on the scale. Just to back up, the PAD, or pharmacologically active dose, for ERAS-0015 is 16 milligrams on the low end and then 32 milligrams on the high end. It really has differed by indication. I think in pancreatic cancer, which tends to be a little less sensitive to targeted therapy than lung cancer, we've seen more responses more in that 24 to 32 milligram range, and that's why I think especially at 32 milligrams, you just want to put as much drug and get as much exposure as you can. Because from a PK standpoint, we do have dose proportional, we've reported dose proportional increases in exposure from 16 to 24 to 32. We don't have that exposure plateau that's been observed with other molecules within this class.

Jonathan LimChairman and CEO

I think for pancreatic, that really matters. I think we should have, in the July dataset, if we had 15 patients at 24 to 32, hopefully we have maybe more than twice that. With lung cancer, 16 to 32, because it's a more sensitive tumor type, we actually had quite a lot of responses at 16 milligrams in the April dataset. I think now with more patients at 32, at that time, we only had one patient at 32 milligrams responding. I think now with more patients at 32, we'll see if there's more meaningful activity at those higher end of the range.

Paul JengAnalyst

Okay, super. You talked a little bit about the focus indications in lung as well as PDAC, and thinking about a pivotal study at this point. I guess, what does the sort of pathway look like in terms of getting that first study launched? How are you prioritizing lung versus PDAC, and anything about possible timing for getting a study launched?

Jonathan LimChairman and CEO

Yeah, so we're moving as fast as we can. I think based on the data that we've disclosed, we already had the conviction that going into that, we weren't sure if there would be trade-offs of either better safety or better efficacy. But the fact that from April to July, we saw data that convinced ourselves that we were meaningfully better on both sides of that equation, we unlocked and were able to do a pretty significant financing, so that we have the balance sheet to really unlock three pivotal trials, two of which are phase IIIs. On pancreatic cancer, we have high conviction that first-line pancreatic, if we're able to see a difference in second line plus and even third line plus, so heavily pre-treated population, then we think line of treatment does matter, and we should see even better activity in the first-line setting.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day